Anika Therapeutics, Inc. income statement

In fiscal 2025, Anika Therapeutics, Inc. reported revenue of $113m, down 5.9% on the year before, operating income of −$11.1m (a -9.8% margin) and net income of −$10.9m, or −$0.76 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Anika Therapeutics, Inc.: income statement, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	40	56	65	71	75	106	93	103	113	106	115	130	148	114	121	120	113	121
Cost of revenue	—	—	—	—	—	—	—	24	27	31	29	61	65	41	38	44	49	46
Gross profit	—	—	—	—	—	—	—	79	86	74	86	69	83	73	83	76	64	75
Research and development	8	7	6	5	7	8	9	11	19	18	17	23	27	18	22	26	26	27
Selling, general and administrative	11	17	18	15	13	15	15	18	22	34	35	60	74	51	60	56	49	53
Operating income	6	8	14	20	33	61	48	51	46	22	34	−28	3	4	1	−5	−11	−5
Income before tax	6	7	14	20	32	62	48	51	46	23	36	−29	2	4	3	−3	−9	−3
Income tax	2	3	5	8	12	23	17	18	14	4	9	−5	−2	2	7	6	1	0
Net income	4	4	8	12	21	38	31	33	32	19	27	−24	4	−15	−83	−56	−11	−4
Diluted EPS	$0.32	$0.32	$0.62	$0.82	$1.39	$2.51	$2.01	$2.15	$2.11	$1.27	$1.89	−$1.69	$0.28	−$1.02	−$5.64	−$3.83	−$0.76	−$0.27
Diluted shares (average)	12m	14m	14m	14m	15m	15m	15m	15m	15m	15m	14m	14m	15m	15m	15m	15m	14m	14m
EBITDA	7	11	18	24	37	66	52	54	50	28	39	−22	9	10	7	2	−6	1

US$ millions unless shown otherwise. Fiscal quarters.

Anika Therapeutics, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	30	31	26	28	28	31	30	33
Cost of revenue	10	13	11	14	12	11	11	11
Gross profit	19	17	15	14	16	19	19	21
Research and development	6	7	6	6	7	6	7	7
Selling, general and administrative	14	11	13	12	12	12	18	11
Operating income	−0	−1	−4	−4	−3	1	−5	3
Income before tax	0	0	−4	−4	−2	1	−5	3
Income tax	2	3	0	1	1	−1	0	0
Net income	−30	−22	−5	−4	−2	0	−5	3
Diluted EPS	−$2.03	−$1.49	−$0.34	−$0.28	−$0.16	$0.02	−$0.37	$0.24
EBITDA	1	1	−3	−3	−2	2	−4	4

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ANIK vs OM ANIK vs OWLT ANIK vs BBNX ANIK vs RXST

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Anika Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Anika Therapeutics, Inc.